Immune-mediated antitumor effect by type 2 diabetes drug, metformin. - Wikidata - wikimedia - TriplyDB

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

http://www.wikidata.org/entity/Q35089957

about

Repurposing metformin: an old drug with new tricks in its binding pockets A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis Repurposing metformin for cancer treatment: current clinical studies Energy disruptors: rising stars in anticancer therapy?Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance Metabolic regulation of T cell differentiation and function Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination Update on immune checkpoint inhibitors in gynecological cancers Anti-tumor activity of metformin: from metabolic and epigenetic perspectives Metformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer Patients Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis.Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis.Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator.Risk factors for cancer development in type 2 diabetes: A retrospective case-control study Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells Metformin may reduce oral cancer risk in patients with type 2 diabetes Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.Leveraging premalignant biology for immune-based cancer prevention.The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer.NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil.Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.Metformin use and cervical cancer risk in female patients with type 2 diabetes Endogenous AMPK acts as a detrimental factor in fulminant hepatitis via potentiating JNK-dependent hepatocyte apoptosis.Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.Drug repurposing in oncology--patient and health systems opportunities.How does metabolism affect cell death in cancer?Results from 11C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly.Low white blood cell count is independently associated with chronic kidney disease progression in the elderly: the CKD-ROUTE study.Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.Cancer Immunotherapy: Whence and Whither.Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells.Metabolic programming in chronically stimulated T cells: Lessons from cancer and viral infections.Metformin: New Preparations and Nonglycemic Benefits.Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia.

P2860

Q22250976-CA18DEC0-B398-491E-86D6-4575B67946B4 Q26739665-9AB95B90-609C-42F4-BDFA-B84A2F85DE81 Q26746099-35E001EF-2189-4CD3-BEF5-58A8149B33ED Q26752651-3B32D03B-BAFF-41D4-859F-EAA4F701C702 Q26771300-774F0007-30C1-41DE-BADF-213976990E43 Q26775036-B3EB9AC1-3A19-491D-BE94-EDE935F7C9F4 Q26775379-C4590801-0D59-4F76-9658-A54E2FB6A6E5 Q26798088-B46EF584-E241-4D8D-880D-873BEF81D5E1 Q28074536-D4DE4C47-9C0C-4416-B601-50E875653091 Q28076497-5276D235-4C24-47BE-B85A-64986F300C3D Q28080170-09FE697B-D8C5-4C3A-AA7E-5444071CA775 Q28550674-A24550E4-045A-40F8-AE22-2CCC58110F39 Q33605925-0BD26D68-E6D5-4B14-A488-70DE18F5AD72 Q35717532-DBA8AAF8-338C-49D5-A097-918FF513A9FC Q35803926-EB3BDEBB-F06B-45D9-8903-DF53CCCA641D Q36024628-C6CF84D7-2068-4E49-BE47-66FDE04FB03C Q36159846-6F3D3E60-44C4-4DE9-AD0F-9453E1F448A3 Q36289546-CCFCA530-8E38-48C2-BB39-41D3F0640A7D Q36428086-838D31B4-7115-4FCC-B497-795FE250DC5B Q36739022-C5CC2EFF-AF83-443F-BB74-D89D6A50398E Q37274957-D8FFC9B7-9FBD-4BD7-88CA-5B5D8E0228E8 Q37304964-CFA14974-7A1C-4DB1-8FBA-9F5293A95698 Q37501673-7EEE557E-6E5B-4037-A0C8-FC1948D3D26F Q37544605-C6AAFA8A-16E2-4E42-B722-66D7C3C08790 Q37565209-6CAF2D15-789A-4566-A508-361B60662EE0 Q37611667-3C428BDA-7AA0-49AC-82F7-FF585D849322 Q37644891-FFFDA23C-673C-449D-ABFE-D4418409BF57 Q37745507-B374A44A-A8B1-4379-8E8D-9A4156523576 Q37745840-7468991D-2625-4338-9E23-4EF0CD42B9F5 Q38611707-5279D59D-D7BB-4BE7-A2DD-AD9BDAA5D830 Q38615890-025F0EA0-0C49-4B42-8350-AD4F38737652 Q38637111-9CCF8EEA-B0D1-45D6-8BEA-DB620A732BBD Q38683105-6187A617-0B98-4B77-BCF2-5D32650A00A2 Q38692444-18767E4E-C31C-4373-8806-E7FFF8D833E6 Q38703807-44666EBB-4397-4D4B-B237-E74318C14848 Q38737924-EA06786C-7240-44DF-AEAC-762483C4AA9C Q38800502-833D918E-CEF6-40A0-8516-8C22F3E7EB2F Q38857760-8C63FC97-CBF5-4C2A-A05D-385DBA766539 Q39100209-6FBDB1BA-59E5-4810-B801-4E36C40D5E19 Q39111174-01EAD1AE-0C2D-4A15-A8F4-CDD83117F84D

P2860

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

http://www.wikidata.org/entity/Q35089957

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@ast

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@en

type

label

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@ast

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@en

prefLabel

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@ast

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@en

P1433

Q35089957-FDCB08DA-F137-4D6B-88A5-CF0ADE09AA22

P1476

Q35089957-2E58EAC4-8147-4353-B842-3F053A5182EA

P2093

Q35089957-2BE90714-4C9F-4C30-BEDC-D44CAE289101

Q35089957-2BFBC0DB-D6D5-4F96-9982-D7BA6F8F25A0

Q35089957-3CD3DA76-6C52-40DC-82C2-E4BD71BA8544

Q35089957-5824BE71-890E-446D-ADF9-CA64FE568CB9

Q35089957-6420D676-9A7F-4CF9-A0BF-22B4785FA2C9

Q35089957-6AF54D73-CB30-4850-AAAD-B91D38396400

P2860

Q35089957-0596B568-49D8-4E87-849A-6B464090DE18

Q35089957-07982544-BD49-4C46-AF9C-8344F476320B

Q35089957-08E3BB51-340B-44E5-A69D-220693890DC0

Q35089957-09215D6F-C598-4C03-AC51-8309CC0753F1

Q35089957-114CEE4A-3A44-4463-B728-0DCBE49A23E2

Q35089957-20CAF10A-CFA6-4515-9329-E55299B4826A

Q35089957-2E75B055-2113-4C82-9C47-598531D10FA2

Q35089957-2E9B6AAE-A31B-4FF8-BCA8-3E01F3B2BF64

Q35089957-2FAAB753-0C54-4336-8764-8324BBC11D29

Q35089957-310FBF36-84A7-4F86-8C81-2593C12F496E

P304

Q35089957-95838461-8EC3-47C2-9662-B5067140B940

P31

Q35089957-7DA6D161-DE4D-4B5F-8C28-964E01C93CF2

P356

Q35089957-1952A86A-7989-40FD-A3E0-277943C0718F

P407

Q35089957-101D902B-50BD-4FD3-B253-81AC98564C27

P433

Q35089957-5B611648-5FA9-45CE-8508-B426889A9993

P478

Q35089957-001CD056-C85D-45D1-B68C-49B8613A35ED

P577

Q35089957-640E19F1-A682-4025-832F-399A2DD96C8A

P5875

Q35089957-6570DCDF-2B9E-45C8-8673-5BE2E88F6ECE

P698

Q35089957-8B0076A4-833A-4752-8B2C-DC41F59E11EE

P921

Q35089957-A39D0BC9-DE4D-4132-A213-43A047252BD3

Q35089957-C36210A5-FA6E-490A-B5CC-6603F472D093

P932

Q35089957-A3C17C33-0CA6-48FD-85B1-D80EEFF4CC19

P356

PNAS.1417636112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Immune-mediated antitumor effect by type 2 diabetes drug, metformin.

@en

P2093

Chihiro Yamazaki

http://www.w3.org/2001/XMLSchema#string

Eiichi Nakayama

http://www.w3.org/2001/XMLSchema#string

Heiichiro Udono

http://www.w3.org/2001/XMLSchema#string

Mikako Nishida

http://www.w3.org/2001/XMLSchema#string

Shingo Eikawa

http://www.w3.org/2001/XMLSchema#string

Shusaku Mizukami

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

mTOR regulates memory CD8 T-cell differentiation

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

The blockade of immune checkpoints in cancer immunotherapy

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

Central tolerance: learning self-control in the thymus

P304

1809-1814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1417636112

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271519382

http://www.w3.org/2001/XMLSchema#string

P698

25624476

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4330733

http://www.w3.org/2001/XMLSchema#string